Active Post-Market Surveillance of Innovative Devices for Valvular Heart Disease

Starting soon

Conditions studied: Aortic Stenosis, Aortic Regurgitation, Mitral Regurgitation, Tricuspid Regurgitation

In brief

This prospective, multicenter, observational cohort study aims to establish a post-market registry framework to evaluate the real-world clinical applicability, long-term safety, and effectiveness of innovative heart valve devices in China.

Key facts

Study ID

NCT07605624

Run by

Beijing Anzhen Hospital

People needed

5500

Starts

2026-05-10

Expected to finish

2029-01-31

Last updated by the study team

2026-05-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with valvular heart disease (VHD) receiving treatment with prosthetic aortic valve replacement systems (transcatheter and surgical valves), transcatheter mitral valve edge-to-edge repair (TEER) systems, or transcatheter tricuspid valve annuloplasty systems
• Age ≥ 18 years
• Patients who voluntarily participate in the study and sign the informed consent form
• Willing and able to comply with follow-up requirements

Where it is running

• Beijing Anzhen Hospital — Beijing, Beijing Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.